III-01 João Abrantes A repeated time-to-event model for epileptic seizures in patients undergoing antiepileptic drug withdrawal during Video-EEG monitoring Thursday 10:05-11:30 |
III-02 Oliver Ackaert Quantification of the effect of AZD5213 on sleep in subjects with Alzheimer’s disease or mild cognitive impairment using a two state Markov model Thursday 10:05-11:30 |
III-03 Rick Admiraal Population pharmacokinetic modeling of Thymoglobulin in children receiving allogeneic-hematopoietic cell transplantation (HCT): towards individualized dosing to improve survival Thursday 10:05-11:30 |
III-04 Ricardo Alvarez Differences in response to scopolamine between young and elderly healthy adults using a modelling approach: reduction in the central cholinergic system in the elderly? Thursday 10:05-11:30 |
III-05 Claire Ambery Bayesian bio-comparability using small sample sizes and quantification of safety risk Thursday 10:05-11:30 |
III-06 Franc Andreu Solduga Pharmacokinetic modeling of enterohepatic circulation of mycophenolic acid in renal transplant patients. Thursday 10:05-11:30 |
III-07 Natalia Aniceto Population Pharmacokinetics-Pharmacogenetics of Efavirenz using Non-Linear Mixed Effects Modeling and Bayesian Estimation Thursday 10:05-11:30 |
III-08 Manel Aouri Population pharmacokinetics and pharmacogenetics analysis of Rilpivirine in HIV-1 infected individuals Thursday 10:05-11:30 |
III-09 Eduardo Asín-Prieto Population Pharmacokinetics of Daptomycin in Critically Ill Patients Thursday 10:05-11:30 |
III-10 Ioanna Athanasiadou Hyperhydration may alter urine pharmacokinetic profile of drugs: A simulation study using budesonide as model drug Thursday 10:05-11:30 |
III-11 Charlotte Barker Synthesising pragmatic and optimal design: NAPPA - a paediatric penicillin population pharmacokinetic study Thursday 10:05-11:30 |
III-12 Ana Bastos Modeling and simulation of temocillin (TMO) in patients with end stage renal disease undergoing haemodialysis Thursday 10:05-11:30 |
III-13 Francesco Bellanti New dosing recommendations in patients receiving deferiprone chelation therapy in the presence of renal complications Thursday 10:05-11:30 |
III-14 Jan Berkhout Mechanism-based approaches to the analysis of comparative effectiveness in osteoporosis Thursday 10:05-11:30 |
III-15 Julie Bertrand Population approach in high-throughput pharmacogenetics: challenging the maximum likelihood approaches and exploration of a Bayesian alternative Thursday 10:05-11:30 |
III-16 Andrzej Bienczak Population Pharmacokinetic Analysis of Efavirenz in African Children using mixture modelling to describe clearance multimodality. Thursday 10:05-11:30 |
III-17 Sebastien Bihorel KIWI: a collaborative platform for modeling and simulation Thursday 10:05-11:30 |
III-18 Roberto Bizzotto Glucose Homeostasis Modeling: Improvement of the Insulin Kinetics Component Thursday 10:05-11:30 |
III-19 Irina Bondareva Population modeling of steady-state pharmacokinetics of carbamazepine (CBZ) and its epoxide metabolite (CBZE) from therapeutic drug monitoring (TDM) data Thursday 10:05-11:30 |
III-20 Jens Markus Borghardt The physiological interpretation of population pharmacokinetic modelling results for inhaled olodaterol Thursday 10:05-11:30 |
III-21 Dean Bottino Operating Characteristics of Tumor Kinetic Response Assessments in Early Phase Oncology Trials Thursday 10:05-11:30 |
III-22 Ari Brekkan Viggosson Optimized Reduced Designs of Pharmacokinetic Clinical Trials Utilizing Target Mediated Drug Disposition Models Thursday 10:05-11:30 |
III-23 Karl Brendel Population Pharmacokinetic modelling for a molecule S and its glucuronide metabolite including enterohepatic recycling Thursday 10:05-11:30 |
III-24 Frances Brightman Predicting clinical response using preclinical data: translational modelling of docetaxel-thalidomide combination treatment in metastatic, castrate-resistant, prostate cancer Thursday 10:05-11:30 |
III-25 Margreke Brill Midazolam pharmacokinetics following semi-simultaneous oral and intravenous administration in morbidly obese patients before and 1 year after bariatric surgery Thursday 10:05-11:30 |
III-26 Claire Brillac Population PK/PD modeling of tumor growth inhibition in tumor bearing mice: a translational strategy to predict clinical efficacy ? Thursday 10:05-11:30 |
III-27 René Bruno Exposure-Response Modeling and Simulation of lucitanib Induced Dose Limiting Toxicities and Response Categories in Patients with Solid Tumors Thursday 10:05-11:30 |
III-28 Jantine Brussee Modelling and simulation of the effect of L-arginine adjunctive therapy on vascular function in patients with moderately severe malaria Thursday 10:05-11:30 |
III-29 Elisa Calvier Use of semi-physiological covariate model for maturation of glucuronidation to scale from adults to children Thursday 10:05-11:30 |
III-30 Ana Catalan-Latorre A Mechanistic Population Pharmacokinetic Model For Taurine In Well And Undernourished Rats Thursday 10:05-11:30 |
III-31 Juan Pablo Cayun Pellizaris Association between genetic, adverse events and pharmacokinetics in testicular cancer patients. Thursday 10:05-11:30 |
III-32 Pascal Chanu Population pharmacokinetic/pharmacodynamic models to support dose selection of daratumumab in multiple myeloma patients Thursday 10:05-11:30 |
III-33 Aziz Chaouch Population pharmacokinetics of oral voriconazole patients undergoing cataract surgery: modelling concentrations in plasma and in the aqueous humour Thursday 10:05-11:30 |
III-34 Chayan Acharya A diagnostic tool for population models using non-compartmental analysis: nca_ppc functionality for R Thursday 10:05-11:30 |
III-35 Chunli Chen Population pharmacokinetic-pharmacodynamic modelling of rifampicin treatment response in a tuberculosis acute mouse model Thursday 10:05-11:30 |
III-36 Manoranjenni Chetty Exploring fixed dose versus body weight based dosing for monoclonal antibodies using physiologically based pharmacokinetic modelling. Thursday 10:05-11:30 |
III-37 Hyangki Choi Population PKPD modeling of moxifloxacin effect on QT interval prolongation from baseline in Korean and Japanese healthy male and female subjects Thursday 10:05-11:30 |
III-39 Eirini Christodoulou Pharmacokinetics of silibinin in mice tissues and serum after peros and intravenous administration as a HP-ß-CD lyophilized product Thursday 10:05-11:30 |
III-40 Jae Yong Chung Ethnic difference of ADAS-Cog Placebo Response in Patients with Alzheimer's Disease Thursday 10:05-11:30 |
III-41 Laurent Claret A simulation study to assess the impact of time to growth estimation shrinkage on overall survival association Thursday 10:05-11:30 |
III-42 Oskar Clewe A bronchoalveolar lavage study design framework for characterization of the rate and extent of pulmonary distribution Thursday 10:05-11:30 |
III-43 Pieter Colin A model-based analysis of IPEC dosing of paclitaxel in rats. Thursday 10:05-11:30 |
III-44 Teresa Collins Performance of composite and serial study designs for estimation of toxicokinetic parameters. Thursday 10:05-11:30 |
III-45 Emmanuelle Comets Population pharmacokinetics of mycophenolate acid and its metabolite in liver transplant patients Thursday 10:05-11:30 |
III-46 Ana Margarita Contreras Sandoval PK/PD modeling of new immunotherapeutic agents in cancer Thursday 10:05-11:30 |
III-47 Paola Coppola Pharmacokinetic assessment of prulifloxacin in patients with renal impairment using population pharmacokinetics modelling and simulations Thursday 10:05-11:30 |
III-48 Damien Cronier A semi-mechanistic PK/PD model of vemurafenib resistance and its rescue by LY2835219, a cyclin-dependent kinase 4/6 inhibitor, in mice bearing human melanoma xenograft tumours Thursday 10:05-11:30 |
III-49 Chantal Csajka Population Pharmacokinetics of Tamoxifen and three of its metabolites in Breast Cancer patients Thursday 10:05-11:30 |
III-50 Chenhui Deng Within subject variability in pharmacometric count data modeling analysis: dynamic inter-occasion variability and stochastic differential equations Thursday 10:05-11:30 |
III-51 William Denney What is Normal? A Meta-Analysis of Phase 1 Placebo Data Thursday 10:05-11:30 |
III-52 Paolo Denti Population pharmacokinetics of cefazolin in children undergoing elective cardiac surgery Thursday 10:05-11:30 |
III-53 Kristin Dickschen Application of Physiologically-Based Pharmacokinetic/Pharmacodynamic Modelling in Oncology Thursday 10:05-11:30 |
III-54 Paul Matthias Diderichsen Dose selection of GLPG0634, a selective JAK1 inhibitor, for rheumatoid arthritis Phase 2B studies: PK/PD modeling of pSTAT1 biomarker and DAS28 clinical response Thursday 10:05-11:30 |
III-55 Thomas Dorlo Sample size estimates for a clinical trial evaluating allometric dosing of miltefosine in children with visceral leishmaniasis in East Africa Thursday 10:05-11:30 |
III-56 Sameer Doshi Assessing the Influence of the Log-Transform Both Sides (LTBS) Approach on the Type 1 and Type 2 Error Rates for Clearance Estimation when using Bayesian Priors Thursday 10:05-11:30 |
III-57 Ignacio Hernández Imaging procedures help compartmental analysis using nonlinear mixed effect models. Application in the field of non-clinical research. Thursday 10:05-11:30 |
III-58 Janna Duong Linking mechanism-based modelling of type 2 diabetes mellitus with cardiovascular endpoints Thursday 10:05-11:30 |
III-59 Thomas Eissing Target validation and lead optimization in drug development for diabetes using a physiologically-based PK/PD model of the glucose-insulin regulatory system Thursday 10:05-11:30 |